Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co Net Tangible Assets

The Net Tangible Assets of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 21, 2026 is 2.32 B CNY. In the previous year, Net Tangible Assets was 2.29 B CNY — a change of 1.62% (higher).

Net Tangible Assets

2.32 BCNY

YoY

1.62%

Last updated:

Net Tangible Assets of Shanghai InnoStar Bio-tech Co is 2025 2.32 B CNY. Net Tangible Assets of Shanghai InnoStar Bio-tech Co was 2024 2.29 B CNY. It decreases by 1.62% higher compared to the previous year.

The Shanghai InnoStar Bio-tech Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2021
696.99 M CNY
Jan 1, 2022
1.40 B CNY
Jan 1, 2023
1.51 B CNY
Jan 1, 2024
2.29 B CNY
Jan 1, 2025
2.32 B CNY
The Shanghai InnoStar Bio-tech Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
2.32 BCNY+1.62%
2.29 BCNY+51.56%
1.51 BCNY+8.04%
1.40 BCNY+100.34%
696.99 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Net Tangible Assets of Shanghai InnoStar Bio-tech Co is 2.32 B CNY in 2025.

Net Tangible Assets of Shanghai InnoStar Bio-tech Co changed from 2.29 B CNY to 2.32 B CNY, representing a 1.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Shanghai InnoStar Bio-tech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co